1-7 of 7
Carlos Gomez-Roca
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S. Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E. Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (13): 2693–2701.
https://doi.org/10.1158/1078-0432.CCR-23-3567
Published: 01 July 2024
View article titled, Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Open the PDF for Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, Juan Martin-Liberal, Sang Joon Shin, Terence Friedlander, Diego Tosi, Chandler Park, Carlos Gomez-Roca, Florence Joly Lobbedez, Daniel Castellano, Rafael Morales-Barrera, Irene Moreno-Candilejo, Aude Fléchon, Kobe Yuen, Deepali Rishipathak, Kelly DuPree, Fiona Young, Francesca Michielin, Colby S. Shemesh, Elizabeth E. Steinberg, Patrick Williams, Jae Lyun Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4373–4384.
https://doi.org/10.1158/1078-0432.CCR-23-0798
Published: 01 November 2023
View article titled, Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Open the PDF for Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) in another window
Includes: Supplementary data
Journal Articles

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, Carlos Gomez-Roca, Jean-Philippe Metges, Antoine Adenis, Simon Pernot, Carine Bellera, Michèle Kind, Céline Auzanneau, François Le Loarer, Isabelle Soubeyran, Alban Bessede, Antoine Italiano
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2139–2147.
https://doi.org/10.1158/1078-0432.CCR-20-3416
Published: 15 April 2021
View article titled, Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
Open the PDF for Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, Valerie Cristina, Edith Borcoman, Eric Deutsch, Rastislav Bahleda, Valentin Calugaru, Anouchka Modesto, Elisabeth Rouits, Kathrin Gollmer, Gregoire Vuagniaux, Philippa Crompton, Claudio Zanna, Sergio Szyldergemajn, Jean-Pierre Delord, Jean Bourhis
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6429–6436.
https://doi.org/10.1158/1078-0432.CCR-20-0425
Published: 15 December 2020
View article titled, Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F. Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez-Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh-de Parseval, Tim Demuth, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5339–5348.
https://doi.org/10.1158/1078-0432.CCR-16-2923
Published: 15 September 2017
View article titled, Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma
Open the PDF for Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5663–5671.
https://doi.org/10.1158/1078-0432.CCR-14-0719
Published: 13 November 2014
View article titled, Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Open the PDF for Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study in another window
Includes: Supplementary data
Journal Articles

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Serge Koscielny, Antonin Levy, Christophe Massard, Rastislav Balheda, Brian Bot, Carlos Gomez-Roca, Clarisse Dromain, Samy Ammari, Jean-Charles Soria
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 246–252.
https://doi.org/10.1158/1078-0432.CCR-13-2098
Published: 05 January 2014
View article titled, Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Open the PDF for Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials in another window
Includes: Supplementary data